# Patent

## Title
Halogenated diarylacetylenes and methods of treating cancer

## Abstract

Halogenated diarylacetylenes, e.g., diarylacetylenes having at least one halo substituent in one aryl ring and an amine in the opposing aryl ring, can inhibit the proliferation of LS174T colon cancer cells through the inhibition of c-myc and induction of the cyclin-dependent kinase inhibitor-1 (i.e., p21(Wif1/Cip1)). Such compounds are useful as antineoplastic agents.

## Background
CROSS-REFERENCE TO RELATED APPLICATION
This application claims the benefit of U.S. Provisional Application No. 61/970,657 filed Mar. 26, 2014 the entire disclosure of which is hereby incorporated by reference herein.


STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
This invention was made with government support under R21 CA139359 and R01 CA172379. The Government has certain rights in the invention.


TECHNICAL FIELD
The present disclosure relates to halogenated diarylacetylenes for use as antineoplastic agents.
BACKGROUND
A family of fluorinated N,N-dialkylaminostilbene analogs (FIDAS agents) that inhibit the expression of Wnt target genes, such as c-myc, and repress colon cancer cell growth in vitro and in vivo was recently described. See, e.g., J Med Chem 2011: 54:1288-1297; ACS Chem Biol 2013: 8(4):796-803; U.S. Pat. No. 8,664,276.
In addition, certain diarylacetylenes are known for certain medicinal uses. See, e.g., WO2012149049; WO2012149048; WO2010092043; WO2009038759; WO2008073350; and WO2001029011. Further, U.S. Pat. No. 8,716,355 to Tsai discloses hydroxylated tolans and related compounds in the treatment of cancer and Hadfield et al disclose preparation and evaluation of diarylalkynes as antitumor agents. Hadfield et al, Synthetic Communications 1998: 28(8):1421-1431. However, there is an ongoing need for additional compounds that can be used to treat cancer and other ailments.
SUMMARY OF THE DISCLOSURE
Advantages of the present disclosure include halogenated diarylacetylenes and compositions having antineoplastic activity and methods of inhibiting cancer cell growth and/or treating cancer in a patient by administering one or more of the halogenated diarylacetylenes or pharmaceutical compositions thereof.
One aspect of the present disclosure is directed to halogenated diarylacetylenes that are useful for killing hyperproliferating cells such as cancer cells for the treatment of human malignant and benign cancers, including without limitation, colorectal cancer (CRC), breast cancer, lung cancer, prostate cancer and liver cancer. In this aspect of the disclosure, there are provided certain halogenated diarylacetylenes having anti-neoplastic activity against cancerous cells. The halogenated diarylacetylenes of the present disclosure include compounds according to formula (I):




or a pharmaceutically acceptable salt thereof, wherein each of X1 through X5 independently represents H, a lower alkyl, or halo, provided that at least one of X1 through X5 is a halo; and each of Y1 through Y5 independently represents H, a lower alkyl, or NR1R2, provided that at least one of Y1 through Y5 is NR1R2, wherein each of R1 and R2 independently represents H, or a lower alkyl. In one aspect, of the present disclosure the compound of formula (I) does not include groups such as ester, hydroxyl, sulfonamide, amide, urethane, and carboxyl groups.
The halogenated diarylacetylenes of formula (I) or pharmaceutically acceptable salts thereof can be included in a pharmaceutical composition with a pharmaceutically acceptable carrier.
Another aspect of the present disclosure is directed to methods of treating cancer, e.g., inhibiting cancer cell growth and/or inhibiting tumor growth in a mammal, such as a human, or treating diseases associated with hyperproliferating cells. In one embodiment of this aspect of the disclosure, an effective amount of one or more halogenated diarylacetylenes, pharmaceutical salts and/or pharmaceutical compositions thereof is administered to a patient in need of treatment of cancer sufficient to treat/inhibit cancer cell growth in the patient.
In an embodiment of this aspect of the disclosure, a therapeutically effective amount of one or more halogenated diarylacetylenes, pharmaceutical salts and/or pharmaceutical compositions thereof is administered to a patient suffering from colorectal cancer. In another embodiment, a therapeutically effective amount of one or more halogenated diarylacetylenes, pharmaceutical salts and/or pharmaceutical compositions thereof is administered to a patient suffering from liver cancer or prostate cancer.
Additional advantages of the present invention will become readily apparent to those skilled in this art from the following detailed description, wherein only the preferred embodiment of the invention is shown and described, simply by way of illustration of the best mode contemplated of carrying out the invention. As will be realized, the invention is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the invention. Accordingly, the drawings and description are to be regarded as illustrative in nature, and not as restrictive.



BRIEF DESCRIPTION OF THE DRAWINGS
Reference is made to the attached drawings, wherein elements having the same reference numeral designations represent similar elements throughout and wherein:
FIG. 1 is a schematic illustration of the synthesis of halogenated diarylacetylenes 2. Reagents: a, HC≡CHC6H4Y; 0.5% Pd(PPh3)4, 1% CuI, H2O, 75° C., 1-2 h; b, a, HC≡CHC6H4NH2; 0.5% Pd(PPh3)4, 1% CuI, H2O, 75° C., 1-2 h followed by CH3I, K2CO3, acetone, 5 h, 56° C.
FIG. 2 is a blot showing inhibition of c-myc and induction of p21(Wif1/Cip1) by diarylacetylenes 2 in colon cancer cells. LS174T cells were treated with 1 μM of each diarylacetylenes 2 for 36 h. DMSO and 1 were used as control. Cell lysates were analyzed by western blotting with β-tubulin as a loading control.



DETAILED DESCRIPTION OF THE DISCLOSURE
The present disclosure relates to halogenated diarylacetylenes, their salts and their pharmaceutical compositions and methods of inhibiting cancer cell growth and/or treating cancer in a patient by administering one or more of the halogenated diarylacetylenes, a pharmaceutical salt thereof, or a pharmaceutical composition thereof. It was found that halogenated diarylacetylenes having at least one, preferably two, halo substituents in one aryl ring and an amine in the opposing aryl ring, e.g., N-methylamino or N,N-dimethylamino, inhibit the proliferation of LS174T colon cancer cells through the inhibition of c-myc and induction of the cyclin-dependent kinase inhibitor-1 (i.e., p21(Wif1/Cip1)). Such compounds and compositions are useful as antineoplastic agents.
The halogenated diarylacetylenes of the present disclosure include at least one amine group, e.g., a primary, secondary or tertiary amine, on the aryl ring. Such compounds are useful as antineoplastic agents and can be represented by the following formula:




or a pharmaceutically acceptable salt thereof. The substituents of X1 through X5 each independently represent H, a lower alkyl, or halo, provided that at least one of X1 through X5 is a halo. A halo group means an F, Cl, Br, I, or At group. Preferably substituents X1 through X5 include at least two halo groups, e.g., an F and/or Cl. Each of Y1 through Y5 independently represents H, a lower alkyl, or NR1R2, provided that at least one of Y1 through Y5 is NR1R2, wherein each of R1 and R2 independently represents H, or a lower alkyl. In one aspect, of the present disclosure the compound of formula (I) does not include groups such as ester, hydroxyl, sulfonamide, amide, urethane, and carboxyl groups.
The term “lower alkyl” includes saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups having from one to about ten carbons (C1-C10), e.g., from one to about six carbon atoms (C1-C6) in its backbone structure. In one aspect of the present disclosure, the lower alkyl groups specifically include methyl, ethyl, propyl, isopropyl, n-butyl, etc.
Embodiments of the halogenated diarylacetylenes of the present disclosure include wherein at least two of X1 through X5 is are halo groups, e.g., wherein X1 through X5 is either (i) a fluoro and chloro, (ii) both fluoro, (iii) both chloro groups, and wherein both R1 and R2 are lower alkyl groups, e.g., methyl, ethyl, or butyl groups. Preferably X1 and/or X5 are halo groups, e.g., the diarylacetylenes have one or two halogen substituents at ortho-positions relative to the acetylenic linkage, and X2 through X4 are H or a lower alkyl. In some embodiments, the halogenated diarylacetylenes include compounds, or a pharmaceutically acceptable salt thereof, where Y3 is NR1R2, and Y1, Y2, Y4, and Y5 independently represent H, a lower alkyl, or NR1R2. In other embodiments, Y3 is NR1R2, and Y1, Y2, Y4, and Y5 independently represent H or a lower alkyl, e.g. Y1, Y2, Y4, and Y5 represent H. In still further embodiments, at least one of R1, or R2, is a lower alkyl.
In another embodiment of the present disclosure, the halogenated diarylacetylenes include compounds according to formula (II):




or a pharmaceutically acceptable salt thereof, wherein Y3 is NR1R2, and R1, R2, X1 through X5 and are as defined for the compounds of formula (I) including the various embodiments for formula (I). Preferably, at least one of R1, or R2, is a lower alkyl and at least two of X1 through X5 are either (i) a fluoro and chloro, (ii) both fluoro, (iii) both chloro groups. In another embodiment, both R1, and R2, are lower alkyl, e.g., methyl, and at least two of X1 through X5 are either: (i) a fluoro and chloro, (ii) both fluoro, (iii) both chloro groups. In some embodiments, X1 and/or X5 are halo groups, e.g., either a fluoro or chloro group.
Pharmaceutical compositions of the present disclosure include one or more of compounds according to formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. Preferable, pharmaceutical compositions of the present disclosure include one or more of compounds according to formula (II) and a pharmaceutically acceptable carrier.
In one aspect of the present disclosure, the compounds of formula (I) or (II), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable composition thereof is used in the treatment of cancer. The method comprises administering to a patient in need of such treatment an effective amount of one or more of the halogenated diarylacetylenes, a pharmaceutical salt thereof, or a pharmaceutical composition thereof. Embodiments of the method include wherein the cancer treated is selected from the group consisting of colorectal cancer, breast cancer, lung cancer, prostate cancer and liver cancer.
In the course of developing new agents for the treatment of cancers, we identified a family of fluorinated N,N-dialkylaminostilbene analogs (FIDAS agents) that inhibit the expression of Wnt target genes, such as c-myc, and repress colon cancer cell growth in vitro and in vivo. Recently, we found that (E)-4-(2′,6′-difluorostyryl)-N,N-dimethylaniline (1) (FIG. 1) targeted exclusively the catalytic subunit of methionine S-adenosyltransferase-2 (MAT-2). See Zhang et al. ACS Chem Biol 2013: 8(4):796-803. MAT-2 serves as a source of S-adenosylmethionine (SAM) in colorectal and liver cancers where MAT-2 is upregulated. See
Cai et al. Hepatology 1996: 24:1090-1097; Chen et al. Gastroenterology 2007: 133:207-218; Ito et al. Surg Today 2000: 30:706-710; and Liu et al. J Biol Chem 2011: 286:17168-17180.
It is believed that neoplastic tissues make effective use of SAM from this isoform of MAT to manage crucial epigenetic modifications of histone proteins and thereby regulate gene expression. Interference with this process would represent a new approach for developing potential antineoplastic agents. It is believed that the compounds of the present disclosure inhibit c-myc. In addition, the present compounds would avoid the facile E/Z-isomerizations that afflict the stilbenes and complicate pharmacodynamic and pharmacokinetic studies.
The diarylacetylenes 2 (FIG. 1), e.g., compounds of formula (II), are a preferred group of halogenated diarylacetylenes. Prior reports of acetylenic compounds as antineoplastic agents include monoalkylacetylenes from aquatic organisms and diarylacetylenic analogs of combrestatin. See Dembitsky et al. Nat. Prod. Commun. 2006: 1:773-812 and Hadfield et al. Synth. Commun. 1998: 28:1421-1431. The latter compounds showed cytotoxic activity against a murine leukemia cell line and one showed activity as an inhibitor of tubulin polymerization. The Sonogashira coupling of 4-(N,N-dimethylamino)phenylacetylene with various aryl iodides provided access to the desired diarylacetylenes 2 (Table 1). (Additional information about Sonogashira coupling can be found in Bhattacharya et al. Sengupta, S. Tetrahedron Lett. 2004: 47:8733-8736 and Okuro et al. J. Org. Chem. 1993: 58:4716-4721). Prior work from our laboratories established that stilbenes with N-methylamino and N,N-dimethylamino groups in a para-orientation relative to the central double bond as well as 2,6-difluoro, 2-chloro-6-fluoro or 2,6-dichloro halogenation patterns in the other aromatic ring were the most potent analogs in the inhibition of LS174T cell proliferation. See Zhang et al. J Med Chem 2011: 54:1288-1297.
Table 1 below provides IC50 values for the inhibition of LS174T cell proliferation for certain halogenated diarylacetylenes of the present disclosure and stilbene compound 1 as shown in FIG. 1.














TABLE 1












Inhibition of









LS174T Cell









Proliferation


Compound
X1
X2
X3
X4
X5
Y3
IC50 (nM)







1
F



F
N(CH3)2
59 ± 7.5


2a
F



F
NH2
55 ± 7.8


2b
F



F
NHCH3
 23 ± 10.3


2c





N(CH3)2
>3000


2d
F




N(CH3)2
39 ± 6.0


2e
Cl




N(CH3)2
31 ± 3.1


2f

F



N(CH3)2
>3000


2g


F


N(CH3)2
>3000


2h
F
F



N(CH3)2
119 ± 4.6 


2i
F

F


N(CH3)2
56 ± 8.1


2j

F
F


N(CH3)2
>3000


2k

F

F

N(CH3)2
>3000


2l
F


F

N(CH3)2
55 ± 6.0


2m
F



F
N(CH3)2
23 ± 6.0


2n
F



Cl
N(CH3)2
19 ± 5.0


2o
Cl



Cl
N(CH3)2
52 ± 7.1









SAR studies were undertaken for those diarylacetylenes 2 that possessed fluorine or chlorine substituents in one aryl ring and N-methylamino or N,N-dimethylamino in the other aryl ring. We reported previously that stilbenes repressed colon cancer cell proliferation by inhibiting c-myc expression and inducing the cell cycle inhibitor, p21(Wif1/Cip1). See Zhang et al. J Med Chem 2011: 54:1288-1297. The similarity of the diarylacetylenes to the stilbenes also prompted an in silico modeling study of the binding of (E)-4-(2′,6′-difluorostyryl)-N,N-dimethylaniline (1) and 4((2,6-difluorophenyl)ethynyl)-N,N-dimethylaniline (2m). It was believed that para-oriented amino-substituents, such as the N-methylamino and N,N-dimethylamino groups, were associated with potent MAT2A inhibition. Using an artificially constructed homodimer of MAT2A, we observed that 1 and 2m bound to the same active site and that diarylacetylene 2m inhibited MAT2 at concentrations comparable to that of the stilbene 1 (data not shown). Variability in the MAT2A inhibition assay made the measurement of c-myc inhibition a preferred analytical tool for assessing the potency of diarylacetylenes.
We tested the effect of these diarylacetylenes 2 on the proliferation of LS174T colon cancer cells. The expression of c-myc and p21(Wif1/Cip1) were analyzed by western blotting (FIG. 2). The most active diarylacetylenes 2 inhibited c-myc expression at 1 μM concentrations and as expected for a c-myc inhibitor, induced p21(wif1/Cip1) at the same time. Consistent with prior results in the stilbene family, the diarylacetylenes 2 lacking halogen substituents (e.g., 2c) or possessing only one fluorine substituent at a meta- or para-position relative to the acetylenic linkage (e.g., 2g) had very low potency (Table 1). Diarylacetylenes with one or two halogen substituents at ortho-positions relative to the acetylenic linkage (e.g., 2b, 2d, 2e, 2m and 2n) possessed potencies as inhibitors of LS174T cell proliferation that exceeded that of the related stilbene 1 with IC50 values less than 50 nM (Table 1). Isomers of these diarylacetylenes (e.g., 2f, 2g, 2j and 2k) with halogens in meta- or para-positions were significantly less active than the diarylacetylenes with ortho-halogens. Once again, these results are in consistent with the SAR findings in the stilbene family of c-myc inhibitors. Zhang et al. J Med Chem 2011: 54:1288-1297. Finally, the N-methylation pattern in the diarylacetylenes suggested that N-methyl and N,N-dimethylaniline subunits led to equipotent inhibitors of c-myc (i.e., IC50 of 2b≈IC50 of 2m) but the desmethyl analog was considerably less active (IC50 of 2a=55±7.8 nm).
It was found that diarylacetylenes 2 have a dramatic effect on the proliferation of LS174T colon cancer cells by altering the expression of c-myc and thereby inducing p21(Wif1/Cip1). These results are consistent with similar findings using halogenated stilbenes and suggest that diarylacetylenes and stilbenes repress colon cancer proliferation through similar mechanisms.
In an aspect of the present disclosure, the following particular halogenated diarylacetylenes and their pharmaceutical salts and pharmaceutical compositions can be used to treat cancer, CRC: 4-((2,6-Difluorophenyl)ethynyl)aniline (2a); 4-((2,6-Difluorophenyl)ethynyl)-N-methylaniline (2b); N,N-Dimethyl-4-(phenylethynyl)aniline (2c); 4-((2-Fluorophenyl)ethynyl)-N,N-dimethylaniline (2d); 4-((2-Chlorophenyl)ethynyl)-N,N-dimethylaniline (2e); 4-((3-Fluorophenyl)ethynyl)-N,N-dimethylaniline (2f); 4-((4-Fluorophenyl)ethynyl)-N,N-dimethylaniline (2g); 4-((2,3-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2 h); 4-((2,4-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2i); 4-((3,4-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2j); 4-((3,5-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2k); 4-((2,5-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2l); 4-((2,6-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2m), 4-((2-Chloro-6-fluorophenyl)ethynyl)-N,N-dimethylaniline (2n), and/or 4-((2,6-Dichlorophenyl)ethynyl)-N,N-dimethylaniline (2o).
EXAMPLES
The following examples are intended to further illustrate certain preferred embodiments of the invention and are not limiting in nature. Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein.
Cell Proliferation Assay.
LS174T cells were grown in RPMI medium (Mediatech) supplemented with 5% fetal bovine serum and 1% penicillin/streptomycin. For cell proliferation assays, 3×104 cells/well growing in 12-well plates were treated with DMSO or inhibitors. The cell numbers and viability were analyzed by Vi-Cell Cell Viability Analyzer after 4 days. The IC50 values were calculated with GraphPad Prim 5.
Western Blotting.
Western blot was performed as described previously1. The following antibodies were used: anti-c-myc (Epitomics, 1472-1), anti-p21(Wif1/Cip1) (Cell Signaling, 2947), anti-β-tubulin (DSHB, E7).
Materials.
Chemicals were purchased from Sigma Aldrich or Fisher Scientific or were synthesized according to literature procedures. Solvents were used from commercial vendors without further purification unless otherwise noted. Nuclear magnetic resonance spectra were determined on a Varian instrument (1H, 400 MHz; 13C, 100 Mz). High resolution electrospray ionization (ESI) mass spectra were recorded on a LTQ-Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Waltham, Mass., USA). The FT resolution was set at 100,000 (at 400 m/z). Samples were introduced through direct infusion using a syringe pump with a flow rate of 5 μL/min. Purity of compounds was established by combustion analyses by Atlantic Microlabs, Inc., Norcross, Ga. Compounds were chromatographed on preparative layer Merck silica gel F254 unless otherwise indicated.
Synthesis of Diarylacetylenes.
A general procedure for the synthesis of diarylacetylenes 2 involved the addition of 2.0 mmol of arylacetylene to a mixture of 2.1 mmol of an aryliodide, 3.0 mmol of diisoproprylethylamine, 0.02 mmol of Pd(PPh3)4, and 0.02 mmol of CuI in water (7 mL). The mixture was stirred for 1-2 h at 75° C. After cooling, the product was collected by filtration or extracted using dichloromethane and purified by recrystallization and/or chromatography.
Characterization and Analytical Data Fordiarylacetylenes 2.
4-((2,6-Difluorophenyl)ethynyl)aniline (2a)
Purified by chromatography on silica gel using 1:2ethyl acetate-hexane (Rf=0.43). Yield 65%, mp 104-105° C. 1H NMR (DMSO-d6): δ 7.46-7.39 (m, 1H), 7.22 (d, 2H, J=8.8 Hz), 7.20-7.16 (m, 2H), 6.58 (d, 2H, J=8.8 Hz), 5.69 (s, 2H, NH2). 13C NMR (DMSO-d6): δ 161.72 (dd, J1=248.9 Hz, J2=5.3 Hz, two C), 150.21, 132.77 (two C), 129.89 (t, J=9.9 Hz), 113.60 (two C), 111.68 (dd, J1=18.2 Hz, J2=6.1 Hz, two C), 106.96, 101.96 (t, J=19.8 Hz), 102.28 (d, J=2.7 Hz), 73.11. HRMS (ESI) calcd for C14H9F2N [MH+]: 230.07758. Found: 230.07660. Anal. Calcd for C14H9F2N: C, 73.36; H, 3.96. Found: C, 73.10; H, 4.03.
4-((2,6-Difluorophenyl)ethynyl)-N-methylaniline (2b)
To a solution of 200 mg (0.87 mmol) of 2a in acetone (4 mL) was added successively 145 mg (1.04 mmol, 1.2 equiv) of potassium carbonate and 161 mg (1.13 mmol, 1.3 equiv) of iodomethane. The mixture was refluxed for 5 h. After cooling, the product was diluted with water, extracted with dichloromethane, dried over MgSO4 and concentrated. The product was purified by chromatography on silica gel using 1:5ethyl acetate-hexane (Rf=0.48) to afford 68 mg (32%) of 2b. Mp 69-70° C. 1H NMR (CDCl3): δ 7.40 (d, 2H, J=8.8 Hz), 7.24-7.15 (m, 1H), 6.92-6.87 (m, 2H), 6.53 (d, 2H, J=8.8 Hz), 3.95 (br s, 1H), 2.84 (s, 3H). 13C NMR (CDCl3): δ 162.92 (dd, J1=251.2 Hz, J2=5.3 Hz, two C), 149.92, 133.35 (two C), 128.77 (t, J=9.8 Hz), 112.08 (two C), 111.25 (dd, J1=19.0 Hz, J2=6.0 Hz, two C), 110.34, 103.39 (t, J=19.7 Hz), 100.89 (t, J=3.1 Hz), 74.16, 30.48. HRMS (ESI) calcd for C15H11F2N [MH+]: 244.09323. Found: 244.09241. Anal. Calcd for C15H11F2N: C, 74.06; H, 4.56. Found: C, 73.89; H, 4.71.
N,N-Dimethyl-4-(phenylethynyl)aniline (2c)
Purified by recrystallization from hexane. Yield 88%, mp 104-106° C. 1H NMR (DMSO-d6): δ 7.49-7.47 (m, 2H), 7.41-7.33 (m, 5H), 6.71 (d, 2H, J=9.2 Hz), 2.94 (s, 6H). 13C NMR (DMSO-d6): δ 150.10, 132.38 (two C), 130.86 (two C), 128.61 (two C), 127.83, 123.29, 111.84 (two C), 108.41, 90.90, 87.16, 39.66 (two C). HRMS (ESI) calcd for C16H15N [MH+]: 222.12773. Found: 222.12713.
4-((2-Fluorophenyl)ethynyl)-N,N-dimethylaniline (2d)
Purified by recrystallization from hexane. Yield 62%, mp 94-96° C. 1H NMR (DMSO-d6): δ 7.57-7.53 (m, 1H), 7.43-7.34 (m, 3H), 7.31-7.22 (m, 1H), 7.24-7.20 (m, 1H), 6.71 (d, 2H, J=9.2 Hz), 2.95 (s, 6H). 13C NMR (DMSO-d6): δ 161.47 (d, J=246.7 Hz), 150.32, 132.96, 132.46 (two C), 129.91 (d, J=7.6 Hz), 124.64 (d, J=3.8 Hz), 115.55 (d, J=20.5 Hz), 111.81 (two C), 111.63 (d, J=15.2 Hz), 107.83, 96.02 (d, J=3.0 Hz), 80.38, 39.62 (two C). HRMS (ESI) calcd for C16H14FN [MH+]: 240.11830. Found: 240.11726. Anal. Calcd for C16H14FN: C, 80.31; H, 5.90. Found: C, 80.04; H, 6.03.
4-((2-Chlorophenyl)ethynyl)-N,N-dimethylaniline (2e)
Purified by recrystallization from ethanol. Yield 56%, mp 108-110° C. 1H NMR (DMSO-d6): δ 7.60-7.54 (m, 2H), 7.38-7.34 (m, 4H), 6.73 (d, 2H, J=8.8 Hz), 2.96 (s, 6H). 13C NMR (DMSO-d6): δ 150.40, 134.00, 133.33, 132.76, 132.55 (two C), 129.28, 127.27, 122.96, 111.85 (two C), 107.80, 96.27, 84.08, 39.67 (two C). HRMS (ESI) calcd for C16H14ClN [MH+]: 256.08875. Found: 256.08805.
4-((3-Fluorophenyl)ethynyl)-N,N-dimethylaniline (2f)
Purified by recrystallization from hexane. Yield 87%, mp 99-100° C. 1H NMR (DMSO-d6): δ 7.45-7.31 (m, 5H), 7.22-7.17 (m, 1H), 6.71 (d, 2H, J=9.2 Hz), 2.95 (s, 6H). 13C NMR (DMSO-d6): δ 161.90 (d, J=242.8 Hz), 150.30, 132.55 (two C), 130.66 (d, J=8.4 Hz), 127.19 (d, J=2.2 Hz), 125.32 (d, J=9.9 Hz), 117.31 (d, J=22.7 Hz), 115.02 (d, J=21.3 Hz), 111.81 (two C), 107.79, 92.09, 86.07 (d, J=3.0 Hz), 39.64 (two C). HRMS (ESI) calcd for C16H14FN [MH+]: 240.11830. Found: 240.11750. Anal. Calcd for C16H14FN: C, 80.31; H, 5.90. Found: C, 80.03; H, 6.10.
4-((4-Fluorophenyl)ethynyl)-N,N-dimethylaniline (2g)
Purified by recrystallization from methanol. Yield 92%, mp 132-134° C. 1H NMR (DMSO-d6): δ 7.54-7.51 (m, 2H), 7.35 (d, 2H, J=8.8 Hz), 7.24-7.20 (m, 2H), 6.70 (d, 2H, J=9.2 Hz), 2.94 (s, 6H). 13C NMR (DMSO-d6): δ 161.47 (d, J=245.1 Hz), 150.12, 133.07 (d, J=8.4 Hz, two C), 132.35 (two C), 119.74 (d, J=3.8 Hz), 115.80 (d, J=22.1 Hz, two C), 111.83 (two C), 108.26, 90.56, 86.07, 39.65 (two C). HRMS (ESI) calcd for C16H14FN [MH+]: 240.11830. Found: 240.11752.
4-((2,3-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2 h)
Purified by recrystallization from methanol. Yield 65%, mp 104-106° C. 1H NMR (DMSO-d6): δ 7.46-7.37 (m, 4H), 7.24-7.19 (m, 1H), 6.72 (d, 2H, J=8.0 Hz), 2.91 (s, 6H). 13C NMR (DMSO-d6): δ 149.78 (dd, J1=244.4 Hz, J2=11.4 Hz), 149.37 (dd, J1=247.1 Hz, J2=13.8 Hz), 132.62 (two C), 128.15 (d, J=4.0 Hz), 125.14 (d, J=4.6 Hz), 125.06 (d, J=4.6 Hz), 117.21 (d, J=16.7 Hz), 113.87 (d, J=11.4 Hz), 111.80 (two C), 107.20, 97.54 (d, J=3.8 Hz), 79.23 (d, J=4.6 Hz), 39.60 (two C). HRMS (ESI) calcd for C16H13F2N [MH+]: 258.10888. Found: 258.10818. Anal. Calcd for C16H13F2N: C, 74.69; H, 5.09. Found: C, 74.43; H, 5.22.
4-((2,4-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2i)
Purified by recrystallization from methanol. Yield 82%, mp 116-118° C. 1H NMR (DMSO-d6): δ 7.65-7.59 (m, 1H), 7.40-7.34 (m, 3H), 7.15-7.11 (m, 1H), 6.71 (d, 2H, J=9.2 Hz), 2.95 (s, 6H). 13C NMR (DMSO-d6): δ 161.79 (dd, J1=249.3 Hz, J2=12.5 Hz), 150.35, 161.63 (dd, J1=247.8 Hz, J2=11.8 Hz), 134.11 (dd, J1=9.8 Hz, J2=2.3 Hz), 132.44 (two C), 112.15 (dd, J1=22.0 Hz, J2=3.8 Hz), 111.81 (two C), 108.31 (dd, J1=15.6 Hz, J2=4.2 Hz), 107.68, 104.50 (t, J=25.8 Hz), 95.75, 79.35, 39.63 (two C). HRMS (ESI) calcd for C16H13F2N [MH+]: 258.10888. Found: 258.10806. Anal. Calcd for C16H13F2N: C, 74.69; H, 5.09. Found: C, 74.61; H, 5.23.
4-((3,4-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2j)
Purified by recrystallization from methanol. Yield 93%, mp 100-101° C. 1H NMR (DMSO-d6): δ 7.60-7.55 (m, 1H), 7.48-7.41 (m, 1H), 7.37-7.32 (m, 3H), 6.71 (d, 2H, J=9.2 Hz), 2.95 (s, 6H). 13C NMR (DMSO-d6): δ 150.29, 149.21 (dd, J1=249.0 Hz, J2=14.5 Hz, two C), 132.49 (two C), 128.26 (dd, J1=6.4 Hz, J2=3.4 Hz), 128.68 (dd, J1=8.0 Hz, J2=4.2 Hz), 119.76 (d, J=18.2 Hz), 118.00 (d, J=16.7 Hz), 111.80 (two C), 107.69, 91.58, 85.21, 39.62 (two C). HRMS (ESI) calcd for C16H13F2N [MH+]: 258.10888. Found: 258.10787. Anal. Calcd for C16H13F2N: C, 74.69; H, 5.09. Found: C, 74.80; H, 5.11.
4-((3,5-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2k)
Purified by recrystallization from methanol. Yield 84%, mp 72-74° C. 1H NMR (DMSO-d6): δ 7.37 (d, 2H, J=8.8 Hz), 7.28-7.19 (m, 3H), 6.71 (d, 2H, J=9.2 Hz), 2.96 (s, 6H). 13C NMR (DMSO-d6): δ 162.27 (dd, J1=245.1 Hz, J2=14.4 Hz, two C), 150.47, 132.70 (two C), 126.29 (t, J=12.1 Hz), 113.95 (dd, J1=19.0 Hz, J2=7.6 Hz, two C), 111.78 (two C), 107.22, 103.94 (t, J=25.8 Hz), 93.42, 85.33 (t, J=3.8 Hz), 39.60 (two C). HRMS (ESI) calcd for C16H13F2N [MH+]: 258.10888. Found: 258.10787. Anal. Calcd for C16H13F2N: C, 74.69; H, 5.09. Found: C, 74.43; H, 5.20.
4-((2,5-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2l)
Purified by recrystallization from methanol. Yield 79%, mp 106-107° C. 1H NMR (DMSO-d6): δ 7.45-7.41 (m, 1H), 7.39-7.32 (m, 3H), 7.28-7.22 (m, 1H), 6.72 (d, 2H, J=9.2 Hz), 2.96 (s, 6H). 13C NMR (DMSO-d6): δ 157.89 (dd, J1=243.6 Hz, J2=2.3 Hz), 157.80 (dd, J1=239.9 Hz, J2=2.3 Hz), 150.52, 132.62 (two C), 118.82 (d, J=25.8 Hz), 117.04 (dd, J1=24.3 Hz, J2=9.1 Hz), 116.53 (dd, J1=24.3 Hz, J2=8.3 Hz), 113.01 (dd, J1=18.2 Hz, J2=10.7 Hz), 111.80 (two C), 107.23, 97.22 (d, J=3.8 Hz), 79.61, 39.61 (two C). HRMS (ESI) calcd for C16H13F2N [MH+]: 258.10888. Found: 258.10812. Anal. Calcd for C16H13F2N: C, 74.69; H, 5.09. Found: C, 74.56; H, 5.21.
4-((2,6-Difluorophenyl)ethynyl)-N,N-dimethylaniline (2m)
Purified by recrystallization from hexane. Yield 59%, mp 98-100° C. 1H NMR (DMSO-d6): δ 7.49-7.41 (m, 1H), 7.37 (d, 2H, J=8.8 Hz), 7.23-7.18 (m, 2H), 6.72 (d, 2H, J=8.8 Hz), 2.97 (s, 6H). 13C NMR (DMSO-d6): δ 161.75 (dd, J1=248.9 Hz, J2=5.3 Hz, two C), 150.58, 132.59 (two C), 130.12 (t, J=10.3 Hz), 111.76 (dd, J1=17.9 Hz, J2=4.3 Hz, two C), 111.82 (two C), 107.21, 101.83 (t, J=19.8 Hz), 100.88 (t, J=3.1 Hz), 73.83, 39.64 (two C). HRMS (ESI) calcd for C16H13F2N [MH+]: 258.10888. Found: 258.10801. Anal. Calcd for C16H13F2N: C, 74.69; H, 5.09. Found: C, 74.47; H, 5.24.
4-((2-Chloro-6-fluorophenyl)ethynyl)-N,N-dimethylaniline (2n)
Purified by chromatography on silica gel using 1:5ethyl acetate-hexane (Rf=0.74). Yield 53%, mp 86-88° C. 1H NMR (DMSO-d6): δ 7.45-7.30 (m, 5H), 6.73 (d, 2H, J=8.8 Hz), 2.97 (s, 6H). 13C NMR (DMSO-d6): δ 161.89 (d, J=249.7 Hz), 150.62, 135.11 (d, J=3.0 Hz), 132.64 (two C), 129.90 (d, J=9.1 Hz), 125.37 (d, J=3.0 Hz), 114.37 (d, J=21.2 Hz), 112.37 (d, J=18.2 Hz), 111.84 (two C), 107.24, 101.55 (d, J=3.8 Hz), 77.59, 39.64 (two C). HRMS (ESI) calcd for C16H13ClFN [MH+]: 274.07933. Found: 274.07858. Anal. Calcd for C16H13ClFN: C, 70.20; H, 4.79. Found: C, 70.43; H, 4.76.
4-((2,6-Dichlorophenyl)ethynyl)-N,N-dimethylaniline (2o)
Purified by recrystallization from ethanol. Yield 54%, mp 96-98° C. 1H NMR (DMSO-d6): δ 7.52 (d, 2H, J=8.0 Hz), 7.37-7.29 (m, 3H), 6.70 (d, 2H, J=9.2 Hz), 2.93 (s, 6H). 13C NMR (DMSO-d6): δ 150.66, 135.26, 133.31, 132.67 (two C), 129.40, 127.97 (two C), 122.79, 111.82 (two C), 107.22, 101.91, 81.62, 39.61 (two C). HRMS (ESI) calcd for C16H13Cl2N [MH+]: 290.04978. Found: 290.04888. Anal. Calcd for C16H13Cl2N: C, 66.22; H, 4.52. Found: C, 66.06; H, 4.70.
Only the preferred embodiment of the present invention and examples of its versatility are shown and described in the present disclosure. It is to be understood that the present invention is capable of use in various other combinations and environments and is capable of changes or modifications within the scope of the inventive concept as expressed herein. Thus, for example, those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances, procedures and arrangements described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the following claims.

## Claims

1. A method of treating colorectal cancer, the method comprising administering to a patient in need of such treatment an effective amount of a compound according to the following formula:



or a pharmaceutically acceptable salt thereof, wherein each of X1 through X5 independently represents H, a lower alkyl, or halo, provided that at least one of X1 through X5 is a halo; and each of Y1 through Y5 independently represents H, a lower alkyl, or NR1R2, provided that at least one of Y1 through Y5 is NR1R2, wherein each of R1 and R2 independently represents H, or a lower alkyl, provided that at least one of R1 or R2 is a lower alkyl.

2. The method of claim 1, wherein at least two of X1 through X5 are halo groups.

3. The method of claim 2, wherein X1 through X5 are either (i) a fluoro and chloro, (ii) both fluoro, or (iii) both chloro groups.

4. The method of claim 1, wherein both R1 and R2 are lower alkyl groups.

5. The method of claim 4, wherein either X1 or X5 or both X1 and X5 are halo groups and X2 through X4 are H or a lower alkyl.

6. The method of claim 1, wherein X1 and/or X5 are halo groups, X2 through X4 are H or a lower alkyl, Y3 is NR1R2, and Y1, Y2, Y4, and Y5 independently represent H or a lower alkyl.

7. The method of claim 1, wherein X1 and/or X5 are fluoro and/or chloro and at least one of R1 or R2 is a lower alkyl.

8. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to the following formula:



or a pharmaceutically acceptable salt thereof, wherein each of X1 through X5 independently represents H, a lower alkyl, a fluoro or a chloro, provided that at least one of X1 through X5 is a fluoro or chloro; and each of Y1 through Y5 independently represents H, a lower alkyl, or NR1R2, provided that at least one of Y1 through Y5 is NR1R2, wherein each of R1 and R2 independently represents H, or a lower alkyl, provided that at least one of R1 or R2 is a lower alkyl; and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is acceptable to be administered to a mammal.

9. The pharmaceutical composition of claim 8, wherein at least two of X1 through X5 are fluoro, or chloro groups and the remaining X1 through X5 are H.

10. The pharmaceutical composition of claim 8, wherein X1 and X5 are either (i) a fluoro and chloro, (ii) both fluoro, (iii) both chloro groups.

11. The pharmaceutical composition of claim 8, wherein at least one of R1, or R2, is a lower alkyl.

12. The pharmaceutical composition of claim 11, wherein the lower alkyl is methyl or ethyl.